A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

This trial is testing glofitamab — a newer type of immunotherapy drug — in older or frail patients with aggressive B-cell lymphoma (including diffuse large B-cell lymphoma) who have not yet received treatment. It's designed for patients who are typically too weak for standard intensive chemotherapy. **You may be eligible if...** - You are 65-79 years old and have been assessed as unfit or frail, OR you are 80 or older regardless of fitness level - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or transformed lymphoma - You have not yet received any systemic treatment for lymphoma - Your heart function is adequate (ejection fraction of 45% or higher) - You have at least one measurable tumor lesion **You may NOT be eligible if...** - You have already received prior treatment for lymphoma (short-term steroids are an exception) - Your heart function is too weak to tolerate anthracycline-based chemotherapy - Your overall health is too poor (ECOG score above 2) Talk to your doctor to see if this trial is right for you.